press release

May 5, 2017

Alnylam Pharmaceuticals Reports Second Quarter 2011 Financial ResultsCAMBRIDGE, Mass., Aug 01, 2011 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights. "Alnylam remains focused and committed to the advancement of RNAi therapeutics as a whole new class of innovative medicines. Our ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Third Quarter 2011 Financial ResultsCAMBRIDGE, Mass., Nov 01, 2011 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2011, and company highlights. "To date in 2011, we have made solid progress in transforming Alnylam from a platform company to a product company ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) Feb. 9, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2011, and company highlights. “2011 was a year of remarkable clinical achievement for Alnylam and for RNAi therapeutics. Notably, ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports First Quarter 2012 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) May. 3, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights. "We made significant clinical and business progress this quarter, including important achievements with our 'Alnylam 5x15' product development and commercialization strategy. First, we ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Third Quarter 2012 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 5, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights. “The highlights of this quarter include the positive results we reported in our clinical programs and our continued execution on our ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Second Quarter 2012 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 6, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2012, and company highlights. “This was an exceptional quarter and recent period for Alnylam, where we reported positive clinical data from several RNAi therapeutic programs. ...

press release

May 5, 2017

Alnylam Receives Allowance for Broad New European Patent Covering RNAi Therapeutics; New "Kreutzer Limmer II'' Patent Covers RNAi Therapeutics towards over 125 Disease Targets   CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 9, 2005 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the allowance of broad claims from the European Patent Office for a new patent ...

press release

May 5, 2017

.bwcellpaddingbottom1 {padding bottom: 2.0px} .bwcellpaddingbottom3 {padding bottom: 4.0px} .bwcellpaddingleft0 {padding left: 0.0px} .bwcellpaddingleft2 {padding left: 10.0px} .bwcellpaddingleft5 {padding left: 25.0px} .bwcellpaddingright0 {padding right: 0.0px} .bwcellparagraphmargin {margin bottom: 0px; margin top: 0px} .bwdoublebottomborder {border bottom: double black 2.25pt} .bwlistitemmarginbottom {margin bottom: 10.0px} .bwsinglebottomborder {border bottom: solid black 1.0pt} .bwtablebottommargin {margin bottom: 10.0px} .bwtextaligncenter {text align: center} .bwtextalignleft {text align: left} .bwtextalignright {text ...

press release

May 5, 2017

Novartis and Alnylam Create Major Alliance to Discover RNAi Therapeutics   CAMBRIDGE, Mass., Sep 07, 2005 (BUSINESS WIRE) Novartis (NYSE:NVS), and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced today a major multi year alliance focused on the discovery of innovative therapeutics based on RNA interference (RNAi). The alliance will combine the research expertise and understanding of disease mechanism and ...

press release

May 5, 2017

.bwlistitemmarginbottom {margin bottom: 10.0px} .bwtextaligncenter {text align: center} CAMBRIDGE, Mass., May 11, 2010 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of pre clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new study (Akinc ...